BXQ 350

Drug Profile

BXQ 350

Alternative Names: BXQ-350; SapC; SapC-DOPS; Sphingolipid activator protein C

Latest Information Update: 30 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bexion Pharmaceuticals
  • Class Antineoplastics; Phosphatidylserines; Saposins
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Glioblastoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Glioma; Solid tumours

Most Recent Events

  • 28 Nov 2017 Cytovance Biologics agree to develop BXQ 350 for planned phase II clinical trials for Bexion Pharmaceuticals
  • 28 Nov 2017 Bexion Pharmaceuticals plans phase II trials for Solid tumours and Glioma
  • 01 Nov 2017 Bexion Pharmaceuticals and CTI Clinical Trial and Consulting initiate a phase Ib trial for Solid tumours (Late-stage disease, In adults)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top